Akero Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 55.19 million compared to USD 23.06 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 0.49 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.02 USD | +2.01% | -4.95% | -14.51% |
02:00pm | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
Mar. 08 | Akero Therapeutics Raises $367 Million From Share Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.51% | 1.36B | |
-3.19% | 102B | |
+1.65% | 96.29B | |
+2.13% | 22.18B | |
-15.65% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.94% | 16.36B | |
+5.87% | 13.97B | |
+33.29% | 12.17B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023